If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.57
Bid: 0.55
Ask: 0.60
Change: -0.005 (-0.87%)
Spread: 0.05 (9.091%)
Open: 0.60
High: 0.60
Low: 0.57
Prev. Close: 0.575
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Subscription and Notice of General Meeting

25 Sep 2009 07:00

RNS Number : 6504Z
Provexis PLC
25 September 2009
 



25 September 2009

Provexis plc

("Provexis" or the "Company")

Proposed Subscription and Notice of General Meeting

The Company announces a conditional subscription (the "Subscription") with new and existing shareholders of 200,000,000 new ordinary shares ("Subscription Shares") of 0.1 p each ("Ordinary Shares") at a price of 2.5p per share ("Subscription Price") to raise £5 million before fees, expenses and commissions.

The Subscription is in two parts. The Company is proposing to raise £1.024 million (before fees, expenses and commissions) by way of an issue of 40,969,390 new Ordinary Shares ("Initial Subscription Shares") at the Subscription Price conditional, inter alia, on the admission ("Admission") of the shares to trading on the AIM market of the London Stock Exchange (the "Initial Subscription"). Application has been made to the London Stock Exchange and dealings in the Initial Subscription Shares are expected to commence on AIM on 30 September 2009.

The Company is proposing to raise a further £3.976 million (before fees, expenses and commissions) by way of the issue of a further 159,030,610 new Ordinary Shares (the "Second Subscription Shares") at the Subscription Price to the same investors conditional, inter alia, on the passing of resolutions at a general meeting of the Company to authorise the Company to allot the shares and to disapply pre-emption rights (the "Resolutions") and Admission of the shares (the "Second Subscription").

While the Directors believe that the Subscription is in the best interests of the Company and Shareholders as a whole, they consider that all Shareholders should be offered the opportunity to participate at the same price per share as those subscribing for the Initial Subscription Shares and the Second Subscription Shares. However, the Directors consider that an offer to existing Shareholders by way of a rights or other pre-emptive issue is not currently practicable or feasible due to the delays that would be incurred through the production and approval of a prospectus which would have to comply with the Prospectus Rules and be pre-vetted and approved by the FSA. Therefore, the Board intends as soon as reasonably practicable to undertake an open offer or an offer for subscription to be made available to all Shareholders to subscribe for new shares in the Company at 2.5p per share to raise approximately £1.5 million, subject to prevailing market conditions. Any such offer would require the publication by the Company of a prospectus and Shareholders' approval.

The Directors believe that the proceeds of the Subscription will support the Company's strategy in three main areas:

strengthening the balance sheet in order to improve the Company's leverage in current and prospective negotiations for its Fruitflow® technology;

accelerating new claim development for its Fruitflow® and NSP#3G plantain technology; and

the acquisition of new technologies to strengthen the pipeline, thereby enhancing long-term shareholder value. 

The Second Subscription is conditional, inter alia, upon the Resolutions being passed at a general meeting of the Company. The Company expects to send a circular to shareholders on or around 28 September 2009 (the "Circular") convening a general meeting of the Company at which the Resolutions will be proposed for approval. The Second Subscription is further conditional on Admission of the Subscription Shares taking place on 16 October 2009 (or on a date not later than 30 October 2009).

The Initial Subscription Shares and the Second Subscription Shares will rank pari passu in all respects with the Company's existing Ordinary Shares, including the right to receive all dividends and other distributions declared following Admission.

The Subscription Price represents a discount of approximately 72.2 per cent. to the closing mid-market price of 9.0 pence per Ordinary Share on 24 September 2009, being the last dealing day prior to this announcement. The Initial Subscription Shares and the Second Subscription Shares will in aggregate represent approximately 19.56 per cent. of the Company's enlarged issued ordinary share capital after the issue of the Initial Subscription Shares and the Second Subscription Shares.

Following admission of the Second Subscription Shares, the Company's issued ordinary share capital will be 1,022,539,965 Ordinary Shares. The Company does not hold any shares in treasury. This figure of 1,022,539,965 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Stephen Moon, Chief Executive of the Company, commented:

"The proceeds of the Subscription will significantly strengthen our balance sheet, putting us in a stronger position when negotiating commercial arrangements for our patented, scientifically-proven Fruitflow heart-health technology. It will also enable the Company to explore and accelerate the development of new claims for Fruitflow and our NSP#3G plantain technology for the treatment of inflammatory bowel disease-related conditions. Finally, this substantial injection of capital will enable management to explore the acquisition of new functional and medical food technologies to strengthen the pipeline and enhance long-term shareholder value."

For further information please contact:

Provexis plc Tel: 01753 752290

Stephen Moon, Chief Executive

Ian Ford, Finance Director

Arbuthnot Securities Tel: 020 7012 2000

Tom Griffiths/Alasdair Younie

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEIFFFIAAISFIA
Date   Source Headline
9th Jan 20124:35 pmRNSPrice Monitoring Extension
9th Jan 20127:00 amRNSProvexis to fuel GB rowing team
7th Dec 20113:01 pmRNSAdditional Listing
1st Dec 20117:00 amRNSChange of adviser
1st Dec 20117:00 amRNSInterim Results
28th Nov 20117:00 amRNSNotice of Interim Results
8th Nov 20117:00 amRNSRenewal of £25 million Equity Financing Facility
24th Aug 20113:24 pmRNSResult of AGM
24th Aug 20117:00 amRNSAGM Statement
8th Aug 20114:40 pmRNSSecond Price Monitoring Extn
8th Aug 20114:35 pmRNSPrice Monitoring Extension
4th Aug 20114:40 pmRNSSecond Price Monitoring Extn
4th Aug 20114:35 pmRNSPrice Monitoring Extension
1st Aug 20115:22 pmRNSNotice of AGM
29th Jul 20117:00 amRNSTotal Voting Rights
26th Jul 20114:46 pmRNSResult of open offer
15th Jul 20114:35 pmRNSHolding(s) in Company
14th Jul 201110:44 amRNSHolding(s) in Company
12th Jul 20114:23 pmRNSHolding(s) in Company
12th Jul 20119:17 amRNSHolding(s) in Company
11th Jul 20111:42 pmRNSChange of Registered Office
5th Jul 20117:00 amRNSOpen Offer
30th Jun 20114:55 pmRNSHolding(s) in Company
30th Jun 20117:00 amRNSTotal Voting Rights
28th Jun 20113:34 pmRNSHolding(s) in Company
24th Jun 201112:08 pmRNSCompletion of the acquisition of SiS
20th Jun 20119:36 amRNSDirector Dealing
17th Jun 20114:15 pmRNSGrant of Options
17th Jun 20117:00 amRNSFinal Results
17th Jun 20117:00 amRNSAcquisition of Science in Sport Ltd
1st Jun 20117:00 amRNSUpdate on Crohn's disease trial
1st Jun 20117:00 amRNSAppointment of New Product Director
1st Jun 20117:00 amRNSSigning of Development Agreement
31st Mar 20117:00 amRNSPre-close update
28th Feb 20118:49 amRNSDevelopment Agreement - Replacement announcement
28th Feb 20117:00 amRNSDevelopment Agreement with DSM Nutritional Product
8th Feb 20114:35 pmRNSPrice Monitoring Extension
16th Dec 20107:00 amRNSINTERIM RESULTS
9th Dec 20107:00 amRNSNotice of Results
17th Nov 20107:00 amRNSFruitflow wins industry innovation awards
29th Oct 20107:00 amRNSTotal Voting Rights
27th Oct 20104:40 pmRNSSecond Price Monitoring Extn
27th Oct 20104:35 pmRNSPrice Monitoring Extension
14th Oct 20101:38 pmRNSHolding(s) in Company
11th Oct 201011:53 amRNSHolding(s) in Company
4th Oct 20107:00 amRNSIssue of Equity
13th Sep 20104:24 pmRNSHolding(s) in Company
9th Sep 20103:17 pmRNSResult of AGM
9th Sep 20107:00 amRNSAGM Statement
7th Sep 20104:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.